GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom – Revolo Biotherapeutics, a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, a first-in-class...
Latest News
REDWOOD CITY, Calif. — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluating daraxonrasib as monotherapy and in combination with chemotherapy in patients with previously untreated metastatic...
REDWOOD CITY, Calif. — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal...
Ulsan, South Korea – A research team, affiliated with Ulsan National Institute of Science & Technology (UNIST), has unveiled a novel method to produce a selective anticancer precursor substance that targets and eliminates cancer cells. This groundbreaking method, previously existing only in theory, has now been experimentally proven for the...
Seoul, South Korea – Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as bladder removal followed by artificial bladder implantation or the use of a urine pouch,...
Tokyo, Japan – In today’s medical landscape, precision medicine and targeted therapies are gaining traction for their ability to tailor treatments to individual patients while minimizing adverse effects. Conventional methods, such as gene transfer techniques, show promise in delivering therapeutic genes directly to cells to address various diseases. However, these...
Barcelona, Spain – Different types of cancer have unique molecular ‘fingerprints’ which are detectable in early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in just a few hours, according to a study published today in the journal Molecular Cell. The discovery...
NEW YORK, NY – Using artificial intelligence, Ludwig Cancer Research scientists have developed a powerful predictive model for identifying the most potent cancer killing immune cells for use in cancer immunotherapies. Combined with additional algorithms, the predictive model, described in the current issue of the journal Nature Biotechnology, can be...
Edmonton, Alberta – A new case report published in the peer-reviewed OMICS: A Journal of Integrative Biology describes how longitudinal multi-omics monitoring (LMOM) helped to detect a precancerous pancreatic tumor and led to a successful surgical intervention. Click here to read the article. The patient had undergone annual blood-based LMOM, in which 143 endogenous...
By Raffaele Pereno STOCKHOLM, Sweden – Aegle Therapeutics, a clinical-stage biopharmaceutical company, is pioneering the use of extracellular vesicle (EV) therapies derived from mesenchymal stem cells (MSCs) to treat rare and severe immuno-dermatological diseases. During Biotech Showcase 2025, Aegle presented its lead product, AGLE-102™, as a first-in-class therapy for Dystrophic...